{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:13:25Z","timestamp":1790230405645,"version":"4.1.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C18027\/A15790"],"award-info":[{"award-number":["C18027\/A15790"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","award":["CLL10"],"award-info":[{"award-number":["CLL10"]}],"id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13063-017-2138-6","type":"journal-article","created":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T12:13:34Z","timestamp":1503404014000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial"],"prefix":"10.1186","volume":"18","author":[{"given":"Laura","family":"Collett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena R.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha","family":"Munir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"McParland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie B.","family":"Oughton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy C.","family":"Rawstron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hockaday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Dimbleby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hulme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Allsup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Bloor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hillmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,22]]},"reference":[{"key":"2138_CR1","unstructured":"Haematology Malignancy Research Network. Available from: https:\/\/www.hmrn.org\/statistics\/disorders\/19 . Accessed 12 Apr 2013."},{"issue":"9747","key":"2138_CR2","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised open-label, phase 3 trial. Lancet. 2010;376(9747):1164\u201374.","journal-title":"Lancet"},{"issue":"Sppl 4","key":"2138_CR3","first-page":"Abstract 153","volume":"22","author":"R Advani","year":"2011","unstructured":"Advani R, Sharman J, Smith S. The BTK inhibitor PCI-32765 is highly active and well tolerated in patients (pts) with relapsed\/refractory B cell malignancies: final results from a phase I study. Ann Oncol. 2011;22(Sppl 4):Abstract 153.","journal-title":"Ann Oncol"},{"issue":"3","key":"2138_CR4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213\u201323.","journal-title":"N Engl J Med"},{"issue":"25","key":"2138_CR5","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425\u201337.","journal-title":"N Engl J Med"},{"issue":"12","key":"2138_CR6","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446\u201356.","journal-title":"Blood"},{"issue":"9","key":"2138_CR7","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1586\/era.11.118","volume":"11","author":"S Molica","year":"2011","unstructured":"Molica S. Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial. Expert Rev Anticancer Ther. 2011;11(9):1333\u201340.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"2138_CR8","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","volume":"35","author":"PC O\u2019Brien","year":"1979","unstructured":"O\u2019Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35(3):549\u201356.","journal-title":"Biometrics"},{"key":"2138_CR9","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). 2010. Available from: http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf . Accessed 18 Aug 2017."},{"issue":"2","key":"2138_CR10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"D Cox","year":"1972","unstructured":"Cox D. Regression models and life-tables. J R Stat Soc Ser B. 1972;34(2):187\u2013200.","journal-title":"J R Stat Soc Ser B"},{"key":"2138_CR11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-017-2138-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T12:08:41Z","timestamp":1719403721000},"score":1,"resource":{"primary":{"URL":"http:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-017-2138-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,22]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2138"],"URL":"https:\/\/doi.org\/10.1186\/s13063-017-2138-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,22]]},"article-number":"387"}}